- Home
- GYRE vs PSFE Comparison
GYRE vs PSFE Comparison
Compare GYRE & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- PSFE
- Stock Information
- Founded
- GYRE 2002
- PSFE 1996
- Country
- GYRE United States
- PSFE United Kingdom
- Employees
- GYRE N/A
- PSFE N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- PSFE Business Services
- Sector
- GYRE Health Care
- PSFE Consumer Discretionary
- Exchange
- GYRE Nasdaq
- PSFE Nasdaq
- Market Cap
- GYRE 1.3B
- PSFE 1.4B
- IPO Year
- GYRE N/A
- PSFE N/A
- Fundamental
- Price
- GYRE $13.12
- PSFE $17.68
- Analyst Decision
- GYRE
- PSFE Hold
- Analyst Count
- GYRE 0
- PSFE 6
- Target Price
- GYRE N/A
- PSFE $19.40
- AVG Volume (30 Days)
- GYRE 53.3K
- PSFE 372.6K
- Earning Date
- GYRE 11-13-2024
- PSFE 11-13-2024
- Dividend Yield
- GYRE N/A
- PSFE N/A
- EPS Growth
- GYRE N/A
- PSFE N/A
- EPS
- GYRE N/A
- PSFE N/A
- Revenue
- GYRE $105,033,000.00
- PSFE $1,699,306,000.00
- Revenue This Year
- GYRE $25.32
- PSFE $9.80
- Revenue Next Year
- GYRE $12.95
- PSFE $7.00
- P/E Ratio
- GYRE N/A
- PSFE N/A
- Revenue Growth
- GYRE N/A
- PSFE 8.22
- 52 Week Low
- GYRE $8.26
- PSFE $10.05
- 52 Week High
- GYRE $30.40
- PSFE $26.25
- Technical
- Relative Strength Index (RSI)
- GYRE 41.11
- PSFE 31.53
- Support Level
- GYRE $13.07
- PSFE $22.59
- Resistance Level
- GYRE $19.00
- PSFE $26.25
- Average True Range (ATR)
- GYRE 1.16
- PSFE 0.99
- MACD
- GYRE -0.21
- PSFE -0.51
- Stochastic Oscillator
- GYRE 7.39
- PSFE 9.06
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet, and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.